New York, December 11, 2013 -- Moody's Investors Service has assigned an overall covenant quality score of 3.48 to Salix Pharmaceuticals, Ltd.'s$750m _% Senior Notes due 2021. Subscribers can read the full report at: https://www.moodys.com/research/Salix-Pharmaceuticals-Ltd-Pre-Sale-Snapshot-750m-Senior-Notes-due-Covenant-Quality-Assessment--PBC_161482 . Moody's scores covenant protections on a five-point scale, with 1.0 denoting the strongest covenant protections for investors and 5.0, the weakest. Salix Pharmaceuticals, Ltd.'s score compares with the US average of 3.52 and the peer group average of 3.70.

Vollständigen Artikel bei Moodys lesen